PD L1 News and Research

RSS
Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics enters into clinical trial collaboration agreement with MSD

Specific gut bacteria can improve cancer immunotherapy, show studies

Specific gut bacteria can improve cancer immunotherapy, show studies

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab may change treatment strategies for refractory lung cancer patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

AstraZeneca presents lung cancer research data at WCLC 2015

AstraZeneca presents lung cancer research data at WCLC 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.